Neoantigen-reactive t cells: The driving force behind successful melanoma immunotherapy

9Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Patients with metastatic cutaneous melanoma have experienced significant clinical responses after checkpoint blockade immunotherapy or adoptive cell therapy. Neoantigens are mutated proteins that arise from tumor-specific mutations. It is hypothesized that the neoantigen recognition by T cells is the critical step for T-cell-mediated anti-tumor responses and subsequent tumor regressions. In addition to describing neoantigens, we review the sentinel and ongoing clinical trials that are helping to shape the current treatments for patients with cutaneous melanoma. We also present the existing evidence that establishes the correlations between neoantigen-reactive T cells and clinical responses in melanoma immunotherapy.

Cite

CITATION STYLE

APA

Davis, L., Tarduno, A., & Lu, Y. C. (2021, December 1). Neoantigen-reactive t cells: The driving force behind successful melanoma immunotherapy. Cancers. MDPI. https://doi.org/10.3390/cancers13236061

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free